Escolar Documentos
Profissional Documentos
Cultura Documentos
clinical practice
This Journal feature begins with a case vignette highlighting a common clinical problem.
Evidence supporting various strategies is then presented, followed by a review of formal guidelines,
when they exist. The article ends with the author’s clinical recommendations.
the infection are confirmed gastric or duodenal particularly useful in clinical practice for identi-
ulcers and gastric MALT lymphoma.22,23 Testing fying patients with ulcer dyspepsia and those
for infection, and subsequent eradication, also with nonulcer dyspepsia.29
seems prudent after resection of early gastric can- In randomized trials comparing a noninvasive
cers.24 In addition, European guidelines recom- test-and-treat strategy with early endoscopy26,27
mend eradicating H. pylori infection in first-degree or with proton-pump–inhibitor therapy,30,31 the
relatives of patients with gastric cancer and in three strategies resulted in a similar degree of
patients with atrophic gastritis, unexplained iron- symptom improvement, but early endoscopy was
deficiency anemia, or chronic idiopathic thrombo- more expensive than the other two strategies. 32
cytopenic purpura, although the data in support However, the test-and-treat strategy is unlikely
of these recommendations are scant.23 to be cost-effective in populations with a preva-
Patients with uninvestigated, uncomplicated lence of H. pylori infection below 20%.33 Infor-
dyspepsia may also undergo testing for H. pylori mation is lacking on the longer-term outcomes
infection by means of a nonendoscopic (noninva- of these strategies.
sive) method22,23,25; eradication therapy is pre-
scribed for patients with positive test results. Tests for H. pylori Infection
The rationale for this strategy is that in some pa- Table 1 summarizes the various tests for H. pylori
tients with dyspepsia, underlying H. pylori–induced infection.
ulcer disease is causing their symptoms. This
nonendoscopic strategy is not appropriate for Nonendoscopic Tests
patients with accompanying alarm symptoms Serologic testing for IgG antibodies to H. pylori is
(e.g., weight loss, persistent vomiting, or gastro- often used to detect infection. However, a meta-
intestinal bleeding) or for older patients (≥45 or analysis of studies of several commercially avail-
≥55 years of age, depending on the specific set able quantitative serologic assays showed an
of guidelines) with new-onset dyspepsia, in whom overall sensitivity and specificity of only 85% and
endoscopy is warranted.22,23,25 The nonendoscopic 79%, respectively.34 The appropriate cutoff values
strategy is also not generally recommended for vary among populations, and the test results are
patients with NSAID-associated dyspepsia, since often reported as positive, negative, or equivocal.
NSAIDs can cause ulcers in the absence of H. py- Also, this test has little value in confirming erad-
lori infection. ication of the infection, because the antibodies
An attraction of the test-and-treat strategy is persist for many months, if not longer, after
that it avoids the discomfort and costs of endos- eradication.
copy. However, because only a minority of pa- The urea breath test involves drinking 13C-
tients with dyspepsia who have a positive H. pylori labeled or 14C-labeled urea, which is converted
test have underlying ulcer disease, 26,27 most pa- to labeled carbon dioxide by the urease in H. py-
tients treated by means of the test-and-treat strat- lori. The labeled gas is measured in a breath
egy incur the inconvenience, costs, and potential sample. The test has a sensitivity and a specific-
side effects of therapy without a benefit. In a ity of 95%.35 The infection can also be detected
placebo-controlled trial of empirical treatment by identifying H. pylori–specific antigens in a
involving 294 patients with uninvestigated dys- stool sample with the use of polyclonal or mono-
pepsia and a positive H. pylori breath test, the clonal antibodies (the fecal antigen test).36 The
1-year rate of symptom resolution was 50% in monoclonal-antibody test (which also has a
those receiving H. pylori–eradication therapy, as specificity and a sensitivity of 95%36) is more
compared with 36% of those receiving placebo accurate than the polyclonal-antibody test. For
(P = 0.02)28; 7 patients would need to receive both the breath test and the fecal antigen test,
eradication therapy for 1 patient to have a benefit. the patient should stop taking proton-pump in-
A greater benefit would be expected if treatment hibitors 2 weeks before testing, should stop tak-
were limited to patients with an increased prob- ing H2 receptor antagonists for 24 hours before
ability of having an ulcer. However, neither the testing, and should avoid taking antimicrobial
characteristics of the symptoms nor the presence agents for 4 weeks before testing, since these
of other risk factors for ulcer (e.g., male sex, medications may suppress the infection and re-
smoking, and family history of ulcer disease) are duce the sensitivity of testing.
Urea breath test High negative and positive predictive values; False negative results possible in the presence of PPIs or with
useful before and after treatment recent use of antibiotics or bismuth preparations; consid-
erable resources and personnel required to perform test
Fecal antigen test High negative and positive predictive values with Process of stool collection may be distasteful to patient;
monoclonal-antibody test; useful before and false negative results possible in the presence of PPIs or
after treatment with recent use of antibiotics or bismuth preparations
Endoscopic
Urease-based tests Rapid, inexpensive, and accurate in selected False negative results possible in the presence of PPIs or
patients with recent use of antibiotics or bismuth preparations
Histologic assessment Good sensitivity and specificity Requires trained personnel
Culture Excellent specificity; provides opportunity to test Variable sensitivity; requires trained staff and properly
for antibiotic sensitivity equipped facilities
timal management of recurrent or persistent dys- other potential reasons for the symptoms should
pepsia after noninvasive testing and treatment of also be reconsidered.
H. pylori infection. Options include symptomatic Dr. McColl reports receiving lecture fees from AstraZeneca
acid-inhibitory therapy, endoscopy to check for and Nycomed and consulting fees from Sacoor. No other poten-
tial conflict of interest relevant to this article was reported.
underlying ulcer or another cause of symptoms, Disclosure forms provided by the author are available with the
and repeat of the H. pylori test-and-treat strategy; full text of this article at NEJM.org.
References
1. Warren JR, Marshall BJ. Unidentified 12. Leung WK, Lin SR, Ching JY, et al. C, et al. Current concepts in the manage-
curved bacilli on gastric epithelium in ac- Factors predicting progression of gastric ment of Helicobacter pylori infection: the
tive chronic gastritis. Lancet 1983;1:1273-5. intestinal metaplasia: results of a ran- Maastricht III consensus report. Gut 2007;
2. Everhart JE. Recent developments in domised trial on Helicobacter pylori eradi- 56:772-81.
the epidemiology of Helicobacter pylori. cation. Gut 2004;53:1244-9. 24. Fukase K, Kato M, Kikuchi S, et al.
Gastroenterol Clin North Am 2000;29: 13. Malfertheiner P, Sipponen P, Naumann Effect of eradication of Helicobacter py-
559-79. M, et al. Helicobacter pylori eradication lori on incidence of metachronous gastric
3. Woodward M, Morrison C, McColl K. has the potential to prevent gastric can- carcinoma after endoscopic resection of
An investigation into factors associated cer: a state-of-the-art critique. Am J Gas- early gastric cancer: an open-label, ran-
with Helicobacter pylori infection. J Clin troenterol 2005;100:2100-15. domised controlled trial. Lancet 2008;372:
Epidemiol 2000;53:175-81. 14. Parsonnet J, Hansen S, Rodriguez L, 392-7.
4. Marshall BJ, Barrett LJ, Prakash C, et al. Helicobacter pylori and gastric lym- 25. Talley NJ, Vakil N, Practice Parame-
McCallum RW, Guerrant RL. Urea pro- phoma. N Engl J Med 1994;330:1267-71. ters Committee of the American College
tects Helicobacter (Campylobacter) pylori 15. Fischbach W, Goebeler-Kolve ME, of Gastroenterology. Guidelines for the
from the bactericidal effect of acid. Gas- Dragosics B, Greiner A, Stolte M. Long management of dyspepsia. Am J Gastro-
troenterology 1990;99:697-702. term outcome of patients with gastric enterol 2005;100:2324-37.
5. el-Omar EM, Penman ID, Ardill JES, marginal zone B cell lymphoma of mu- 26. McColl KEL, Murray LS, Gillen D, et
Chittajallu RS, Howie C, McColl KEL. cosa associated lymphoid tissue (MALT) al. Randomised trial of endoscopy with
Helicobacter pylori infection and abnor- following exclusive Helicobacter pylori testing for Helicobacter pylori compared
malities of acid secretion in patients with eradication therapy: experience from a with non-invasive H pylori testing alone
duodenal ulcer disease. Gastroenterology large prospective series. Gut 2004;53: in the management of dyspepsia. BMJ
1995;109:681-91. 34-7. 2002;324:999-1002. [Errata, BMJ 2002;325:
6. Gillen D, el-Omar EM, Wirz AA, Ar- 16. Moayyedi P, Soo S, Deeks J, et al. Sys- 479, 580.]
dill JES, McColl KEL. The acid response to tematic review and economic evaluation 27. Lassen AT, Pedersen FM, Bytzer P,
gastrin distinguishes duodenal ulcer pa- of Helicobacter pylori eradication treat- Schaffalitzky de Muckadell OB. Helico-
tients from Helicobacter pylori-infected ment for non-ulcer dyspepsia. BMJ 2000; bacter pylori test-and-eradicate versus
healthy subjects. Gastroenterology 1998; 321:659-64. prompt endoscopy for management of
114:50-7. 17. Laine L, Schoenfeld P, Fennerty MB. dyspeptic patients: a randomised trial.
7. Hentschel E, Brandstätter G, Drag- Therapy for Helicobacter pylori in patients Lancet 2000;356:455-60.
osics B, et al. Effect of ranitidine and with nonulcer dyspepsia: a meta-analysis 28. Chiba N, Van Zanten SJO, Sinclair P,
amoxicillin plus metronidazole on the of randomized, controlled trials. Ann In- Ferguson RA, Escobedo S, Grace E. Treat-
eradication of Helicobacter pylori and the re- tern Med 2001;134:361-9. ing Helicobacter pylori infection in pri-
currence of duodenal ulcer. N Engl J Med 18. McColl KEL. Absence of benefit of mary care patients with uninvestigated
1993;328:308-12. eradicating Helicobacter pylori in patients dyspepsia: the Canadian adult dyspepsia
8. Axon ATR, O’Moráin CA, Bardhan with nonulcer dyspepsia. N Engl J Med empiric treatment–Helicobacter pylori pos-
KD, et al. Randomised double blind con- 2000;342:589. itive (CADET-Hp) randomised controlled
trolled study of recurrence of gastric ulcer 19. Raghunath A, Hungin AP, Wooff D, trial. BMJ 2002;324:1012-6.
after treatment for eradication of Helico- Childs S. Prevalence of Helicobacter py- 29. The Danish Dyspepsia Study Group.
bacter pylori infection. BMJ 1997;314: lori in patients with gastro-oesophageal Value of the unaided clinical diagnosis in
565-8. reflux disease: systematic review. BMJ dyspepsia patients in primary care. Am J
9. Hansen S, Melby KK, Aase S, Jellum E, 2003;326:737-9. Gastroenterol 2001;96:1417-21.
Vollset SE. Helicobacter pylori infection 20. de Martel C, Llosa AE, Farr SM, et al. 30. Jarbol DE, Kragstrup J, Stovring H,
and risk of cardia cancer and non-cardia Helicobacter pylori infection and the risk Havelund T, Schaffalitzky de Muckadell
gastric cancer: a nested case-control study. of development of esophageal adenocarci- OB. Proton pump inhibitor or testing for
Scand J Gastroenterol 1999;34:353-60. noma. J Infect Dis 2005;191:761-7. Helicobacter pylori as the first step for pa-
10. Infection with Helicobacter pylori. In: 21. Yaghoobi M, Farrokhyar F, Yuan Y, tients presenting with dyspepsia? A cluster-
IARC Working Group on the Evaluation Hunt RH. Is there an increased risk of randomized trial. Am J Gastroenterol
of Carcinogenic Risks to Humans. IARC GERD after Helicobacter pylori eradica- 2006;101:1200-8.
monographs on the evaluation of carcino- tion? A meta-analysis. Am J Gastroenterol 31. Manes G, Menchise A, de Nucci C,
genic risks to humans. Vol. 61. Schisto- 2010 January 19 (Epub ahead of print). Balzano A. Empirical prescribing for dys-
somes, liver flukes and Helicobacter pylori. 22. Chey WD, Wong BCY, Practice Param- pepsia: randomised controlled trial of test
Lyon, France: International Agency for eters Committee of the American College and treat versus omeprazole treatment.
Research on Cancer, 1994:177-240. of Gastroenterology. American College of BMJ 2003;326:1118.
11. Uemura N, Okamoto S, Yamamoto S, Gastroenterology guideline on the man- 32. Delaney BC, Innes MA, Deeks J, et al.
et al. Helicobacter pylori infection and the agement of Helicobacter pylori infection. Initial management strategies for dyspep-
development of gastric cancer. N Engl J Am J Gastroenterol 2007;102:1808-25. sia. Cochrane Database Syst Rev 2001;3:
Med 2001;345:784-9. 23. Malfertheiner P, Megraud F, O’Morain CD001961.
33. Delaney BC, Moayyedi P, Forman D. 39. Fischbach L, Evans EL. Meta-analysis: 44. Lamouliatte H, Mégraud F, Delchier
Initial management strategies for dyspep- the effect of antibiotic resistance status JC, et al. Second-line treatment for failure
sia. Cochrane Database Syst Rev 2003;2: on the efficacy of triple and quadruple to eradicate Helicobacter pylori: a random-
CD001961. first-line therapies for Helicobacter pylori. ized trial comparing four treatment strat-
34. Loy CT, Irwig LM, Katelaris PH, Talley Aliment Pharmacol Ther 2007;26:343-57. egies. Aliment Pharmacol Ther 2003;18:
NJ. Do commercial serological kits for 40. Jafri NS, Hornung CA, Howden CW. 791-7.
Helicobacter pylori infection differ in ac- Meta-analysis: sequential therapy appears 45. Gisbert JP, Morena F. Systematic review
curacy? A meta-analysis. Am J Gastroen- superior to standard therapy for Helico- and meta-analysis: levofloxacin-based res-
terol 1996;91:1138-44. bacter pylori infection in patients naive to cue regimens after Helicobacter pylori
35. Vaira D, Vakil N. Blood, urine, stool, treatment. Ann Intern Med 2008;148:923- treatment failure. Aliment Pharmacol Ther
breath, money, and Helicobacter pylori. 31. [Erratum, Ann Intern Med 2008;149: 2006;23:35-44.
Gut 2001;48:287-9. 439.] 46. Saad RJ, Schoenfeld P, Kim HM, Chey
36. Gisbert JP, Pajares JM. Stool antigen 41. Sánchez-Delgade J, Calvet X, Bujanda L, WD. Levofloxacin-based triple therapy
test for the diagnosis of Helicobacter py- Gisbert JP, Titó L, Castro M. Ten-day se- versus bismuth-based quadruple therapy
lori infection: a systematic review. Helico- quential treatment for Helicobacter pylori for persistent Helicobacter pylori infec-
bacter 2004;9:347-68. eradication in clinical practice. Am J Gas- tion: a meta-analysis. Am J Gastroenterol
37. Midolo P, Marshall BJ. Accurate diag- troenterol 2008;103:2220-3. 2006;101:488-96.
nosis of Helicobacter pylori: urease tests. 42. Gisbert JP, Pajares JM. Helicobacter 47. Qasim A, Sebastian S, Thornton O,
Gastroenterol Clin North Am 2000;29: pylori “rescue” regimen when proton pump et al. Rifabutin- and furazolidone-based
871-8. inhibitor-based triple therapies fail. Ali- Helicobacter pylori eradication therapies
38. Fuccio L, Minardi ME, Zagari RM, ment Pharmacol Ther 2002;16:1047-57. after failure on standard first- and second-
Grilli D, Magrini N, Bazzoli F. Meta-analy- 43. Realdi G, Dore MP, Piana A, et al. Pre- line eradication attempts in dyspepsia pa-
sis: duration of first-line proton-pump treatment antibiotic resistance in Helico- tients. Aliment Pharmacol Ther 2005;21:
inhibitor based triple therapy for Helico- bacter pylori infection: results of three 91-6.
bacter pylori eradication. Ann Intern Med randomized controlled studies. Helico- Copyright © 2010 Massachusetts Medical Society.
2007;147:553-62. bacter 1999;4:106-12.